Clinical Trials Logo

Pancreatic Cancer Non-resectable clinical trials

View clinical trials related to Pancreatic Cancer Non-resectable.

Filter by:

NCT ID: NCT06160323 Recruiting - Clinical trials for Pancreatic Cancer Non-resectable

Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer

Start date: November 10, 2023
Phase: N/A
Study type: Interventional

Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.

NCT ID: NCT05802485 Not yet recruiting - Clinical trials for Pancreatic Cancer Non-resectable

PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT

Start date: April 30, 2023
Phase: N/A
Study type: Interventional

The study consists of a 25 ml blood sample collection: - Before the start of treatment - Approximately 2 months after the start of induction chemotherapy - At the end of induction chemotherapy - Prior to local treatment (radiotherapy, surgery) - At the time of tumor progression Collection of tumor material: - During the initial diagnostic biopsy - On the operating room in case of surgery - At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.

NCT ID: NCT05642962 Recruiting - Pancreatic Cancer Clinical Trials

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Start date: November 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.

NCT ID: NCT05549414 Recruiting - Brain Cancer Clinical Trials

Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System

PPTS
Start date: March 30, 2023
Phase: N/A
Study type: Interventional

This study with Chair-Based, Gantry-less Proton System (CBGS) (aka P-CURE Proton Beam Therapy System or Fixed Beam Chair-based Delivery System) is composed of 3 arms, as following: ARM1: Patients with locally recurrent, previously irradiated thoracic cancer indicated for re- irradiation. ARM2: Patients with recurrent Head and Neck, Brain and Spinal Cord tumors, indicated for re- irradiation. ARM3: Patients with unresectable pancreatic cancer. The primary objectives of the study for all arms are: 1. to describe the efficacy (local control after 3 month) and acute toxicity for patients treated with a fully-integrated CBGS and (2) to compare treatment plans between the fully-integrated CBGS and Photon therapy defined for each patient, based upon OAR sparing for comparable target coverage.

NCT ID: NCT05424159 Recruiting - Clinical trials for Pancreatic Cancer Non-resectable

Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer with pencil beam scanning and simultaneous integrated boost (SIB) technology.

NCT ID: NCT05265663 Recruiting - Clinical trials for Pancreatic Cancer Non-resectable

Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients

PANCOSAR
Start date: October 13, 2020
Phase: N/A
Study type: Interventional

SUMMARY Rationale: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, its incidence increases with age. Many patients with localized (non-metastatic) PC have significant comorbidities, advanced age or a poor performance status which preclude chemotherapy and surgery. Because these patients are currently left untreated, it is desirable to find tolerable treatment options for these patients. A short course of high-dose precise radiation therapy i.e. stereotactic ablative body radiotherapy (SABR) may be feasible in these patients. Review of existing SABR literature for PDAC shows high local control rates, with relatively low toxicity and it was demonstrated to be feasible and well tolerated even in elderly patients. It is unknown whether SABR improves outcomes in this group. The main goal of the current study is to investigate if SABR may relieve tumor-related symptoms, postpone a decrease in global QoL and potentially prolong survival in this patient group compared to the current treatment of choice, best supportive care. Objective: To investigate the potential benefit in survival and quality of life after SABR in patients with localised PDAC for whom no other treatment is available, as compared to controls managed with best supportive care. Study design: A multicentre randomized controlled trial Study population: Patients with biopsy proven, localized PDAC, unfit for chemotherapy and surgery or those who refuse these treatments. They will be randomized between SABR versus best supportive care. Intervention: consists of SABR to the primary tumour in 5 fractions of 8 Gy. Main study endpoints: Primary endpoint is the overall survival rate at six months (from randomization). Secondary endpoints include the evaluation of time to decreased global quality of life (QoL, using the QLQ- C30 and EORTC-PAN26), NRS pain response and Ca19.9 response, acute and subacute toxicity using CTCAEv5.0 and progression-free survival in the treated patients using imaging. It is hypothesized that in frail patients with PDAC, SABR may relieve tumor-related symptoms, improve the quality of life and prolong survival compared to best supportive care. Its aim is to investigate the outcomes of SABR with respect to overall survival, pain response, toxicity and quality of life in patients with non-metastasized PDAC for whom standard radical treatment in the form of surgery or chemotherapy is either too toxic, not possible due to comorbidities, or is refused.

NCT ID: NCT05262452 Recruiting - Chemotherapy Effect Clinical Trials

Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer

Start date: August 9, 2021
Phase: N/A
Study type: Interventional

In patients diagnosed with locally advanced pancreatic cancer (LAPC)/borderline resectable pancreatic cancer (BRPC) and planned chemotherapy using FOLFIRINOX, high intensity focused ultrasound (HIFU)/FOLFIRINOX combined treatment is performed on patients who agree to this study. The combined treatment group is treated in parallel with FOLFIRINOX and HIFU for the first four cycles and then CT is taken for reaction evaluation immediately, 2 months, and 4 months after the four-cycle treatment. For the response assessment, the response rate using RECIST ver. 1.1 and operable rate are evaluated and compared with the results of already established FOLFIRINOX single treatment in the investigators' institute. Time-to-progress and overall survival are calculated.

NCT ID: NCT05047991 Not yet recruiting - Clinical trials for Pancreatic Cancer Non-resectable

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Start date: October 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, open-lable, parallel-controlled phase II study of irinotecan liposome injection-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma. The purpose of this study is to evaluate the differences of safety and efficacy of irinotecan liposome injection-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma.

NCT ID: NCT04986930 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma

SABER
Start date: August 14, 2021
Phase: Phase 2
Study type: Interventional

Modified FOLFIRINOX (mFOLFIRINOX) is the standard of care for patients with locally advanced pancreatic adenocarcinoma. While radiotherapy has been investigated for the management of resectable or locally advanced pancreatic adenocarcinoma, its role in the era of modern chemotherapy is not clear. Stereotactic body radiotherapy (SBRT) is the novel technique of radiotherapy to enhance the dose of radiotherapy to the target tumor lesion. This trial aims to compare the efficacy and safety of mFOLFIRINOX with or without SBRT in patients with locally advanced pancreatic adenocarcinoma

NCT ID: NCT04852367 Withdrawn - Clinical trials for Pancreatic Ductal Adenocarcinoma

PanDox: Targeted Doxorubicin in Pancreatic Tumours

PanDox
Start date: June 16, 2021
Phase: Phase 1
Study type: Interventional

This study will combine focused ultrasound to generate heat, and a heat-sensitive chemotherapy drug (ThermoDox®), delivered into the blood of participants with non-resectable pancreatic cancer. We will compare this to standard delivery of chemotherapy - the drug Doxorubicin given into the blood without the addition of ultrasound. We aim to determine whether the novel approach to delivering chemotherapy with heating the tumour by focused ultrasound can enhance the amount of drug delivered to pancreatic tumours. This will be measured by analysing a biopsy sample of treated tumour.